Longitudinal Follow-Up of Retinopathy and Opticopathy After Treatment With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Medical University of Vienna1 site in 1 country20 target enrollmentNovember 23, 2023

ConditionsUveal Melanoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Uveal Melanoma
Sponsor: Medical University of Vienna
Enrollment: 20
Locations: 1
Primary Endpoint: Incidence and Severity of Retinopathy
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry.

Registry

clinicaltrials.gov

Start Date

November 23, 2023

End Date

June 30, 2025

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Medical University of Vienna

Responsible Party

Principal Investigator

Reinhard Told

MD, PHD

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

•Patients with newly diagnosed uveal melanoma, who will be treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine.